Maze Therapeutics (MAZE) Earnings Analysis

Maze Therapeutics (MAZE) next reports earnings on 2026-08-11, consensus EPS -0.76 USD. Last quarter (2026-03-25) it beat with EPS -0.65 USD vs -0.73 USD est (+11%). It has beaten estimates in 2/3 recent quarters (67%). Trailing P/E -10.36.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does MAZE next report earnings?

Next earnings date2026-08-11
Consensus EPS estimate-0.76 USD
Revenue estimate0.00B

MAZE earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-03-25-0.65 USD-0.73 USD+11%Beat
2025-11-06-0.66 USD-0.74 USD+10.8%Beat
2025-03-31-18.32 USD0.45 USD-4171.1%Miss
2024-09-30-0.56541 USDn/an/an/a

Beat rate: 2/3 (67%) over reported quarters with consensus data.

MAZE valuation and analyst view

Trailing P/E-10.36
Trailing EPS-2.27362 USD
Price / book4.49
Dividend yield0.00%
Market cap1.57B
Analyst consensusBuy (6 buy / 0 hold / 0 sell)
Avg price target54.8 USD

Related research pages

Frequently asked questions

When is Maze Therapeutics (MAZE)'s next earnings date?

Maze Therapeutics is next scheduled to report on 2026-08-11, with a consensus EPS estimate of -0.76 USD and revenue estimate of 0.00B.

Did MAZE beat earnings last quarter?

In its 2026-03-25 report, MAZE posted EPS of -0.65 USD versus a -0.73 USD estimate — a beat of 11%.

What is MAZE's earnings track record?

Over the last 3 reported quarters with consensus data, MAZE beat estimates 2 times (67%).

What is MAZE's current P/E ratio and EPS?

MAZE trades at a trailing P/E of -10.36 on trailing EPS of -2.2736239289242697 USD.

What do analysts rate MAZE?

Analyst consensus is "Buy" across 6 ratings (0 strong buy, 6 buy, 0 hold, 0 sell, 0 strong sell). Average 12-month price target: 54.8 USD.